Restore RP and Optic Nerve Atrophy Vision

01/11/2025

Feedback of UltraVision: We’ve just received some exciting feedback from one of our long-term RP patients who has been consistently following our at-home vision therapy program. After using the new ultrasound stimulation device for over three months, she shared her personal experience and results with us:

I’ve been using the ultrasound stimulation device for some time now.
At first, I honestly wasn’t sure if it was working — I could only hear a faint buzzing sound and didn’t feel much happening. But after reading the manual more carefully and understanding how the device actually stimulates the retina and nerves, I decided to stick with it consistently.

After about three months, I started noticing gradual but meaningful changes. My vision became clearer and sharper, colors appeared brighter and more vibrant, and everything just looked more alive. I’m truly amazed by the improvement and so glad I didn’t give up too soon!

29/10/2025

Restoring Vision After Pituitary Tumor Surgery

When a pituitary tumor presses on the optic chiasm or is removed surgically, it can cause serious damage to the optic nerve—leading to partial or even severe vision loss.

Unfortunately, traditional medicine offers limited solutions for true vision recovery once the optic nerve is injured.

But new advances in bioelectronic and ultrasonic neuromodulation are changing that.

28/10/2025

How Ultrasound Stimulation Can Benefit Wet Macular Degeneration?

Wet macular degeneration is one of the leading causes of vision loss in adults over 60.
It happens when abnormal blood vessels grow under the retina and leak fluid or blood, damaging the macula — the part of the eye responsible for central vision.

Today, researchers are exploring an innovative, noninvasive approach — ultrasound stimulation, also called ultrasonic neuromodulation. This gentle technology uses low-intensity pulsed sound waves to activate and protect the delicate retinal and nerve cells involved in vision.

19/10/2025

Scientists cured a patient’s blindness using only sound waves

This UltraVision device could stimulate dormant or damaged neurons, helping restore some degree of neural signaling or visual perception, especially in degenerative retinal conditions such as RP, Glaucoma, AMD, Stargardt disease, Usher syndrome, Optic Neuritis,

22/09/2025

Why Laser Eye Surgery Is Not Recommended for Retinitis Pigmentosa Patients？

Laser refractive surgery only reshapes the cornea in the front of the eye, not the retina in the back. So why would people with RP—a retinal disease—be advised against it?

24/08/2025

Preventing Blindness with iPS Cells

22/08/2025

Did You Know? – Ultrasound for Glaucoma

Most people know ultrasound as the technology used to see babies before birth. But did you know doctors are now exploring ultrasound as a treatment for eye diseases like glaucoma?

21/08/2025

Mesenchymal Stem Cell-Derived Exosomes in Ophthalmology:
A Comprehensive Review

In recent years, mesenchymal stem cell (MSC) therapy has attracted considerable attention for its potential in treating ophthalmic diseases. While MSCs possess remarkable regenerative, reparative, and immunomodulatory properties, MSC-based therapies still face key limitations, particularly with respect to biocompatibility, tissue pe*******on, and targeted ocular delivery. To address these challenges, researchers have increasingly turned their focus toward MSC-derived exosomes.

Exosomes are nano-sized vesicles that share many of the therapeutic properties of their parent MSCs, including anti-inflammatory, anti-apoptotic, tissue-repairing, neuroprotective, and immunomodulatory effects. Importantly, MSC-derived exosomes may offer advantages as drug-delivery vehicles, as they are capable of penetrating biological barriers—such as the blood-brain barrier—suggesting potential efficacy in crossing the blood-retinal barrier as well. In addition, their cargo is protected from degradation, enhancing stability and increasing bioavailability in ocular tissues.
The following is the original scientific paper published in Pharmaceutics by MDPI.

Over the past decade, the field of mesenchymal stem cell (MSC) therapy has exhibited rapid growth. Due to their regenerative, reparatory, and immunomodulatory capacities, MSCs have been widely investigated as therapeutic agents in the cell-based treatment of chronic ophthalmic pathologies. However,....

21/08/2025

The Future of Non Invasive Eye Care

For patients with optic nerve damage caused by glaucoma or retinal disorders, the need for safe, effective, and accessible solutions continues to grow. Fortunately, rapid progress in medical technology and biotechnology is ushering in a new era of non-invasive eye care—offering gentler, more convenient, and more holistic alternatives to surgery or traditional drug-based treatments.

16/08/2025

How Nasal Conditions Can Influence Eye Pressure: What You Need to Know

In glaucoma, intraocular pressure (IOP) is affected by aqueous humor drainage through the trabecular meshwork and Schlemm’s canal.

Nasal or sinus inflammation generally does not directly block aqueous humor drainage, so it usually has minimal effect on true eye pressure.

However, chronic sinus inflammation might cause orbital congestion or mild venous pressure changes, which can subtly influence IOP in susceptible individuals.

Nasal sprays (especially decongestants like oxymetazoline) can raise IOP in patients with glaucoma, because they cause vasoconstriction and sometimes increase venous pressure in the eye.

Conversely, antihistamines typically have minimal effect on eye pressure.

Coughing, sneezing, or straining due to nasal congestion can temporarily raise eye pressure.

Nasal surgery or trauma can, in rare cases, alter orbital pressure dynamics, which may affect IOP readings temporarily.

10/08/2025

Therapeutic Potential of UC-MSCs in Retinitis Pigmentosa

1. Neuroprotection Through Paracrine Signaling

2. Anti-inflammatory and Immunomodulatory Effects

3. Support for Photoreceptor and Retinal Pigment Epithelium (RPE) Function

4. Early Clinical Evidence of Visual Function Improvement